Search research articles
Contact Us
Filters
Showing results (81-90 of 98) with videos related to
Page
of 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 21, 2017
Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer
Emmanuel S Antonarakis, Scott T Tagawa, Giuseppe Galletti, et al.
Urologic Oncology
|
January 10, 2017
Quality indicators in the management of bladder cancer: A modified Delphi study
Satya R Khare, Armen Aprikian, Peter Black, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education
|
August 6, 2017
Development and Implementation of a Continuing Medical Education Program in Canada: Knowledge Translation for Renal Cell Carcinoma (KT4RCC)
Luke T Lavallée, Ryan Fitzpatrick, Lori A Wood, et al.
European Urology
|
May 20, 2015
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302
Fred Saad, Neal Shore, Hendrik Van Poppel, et al.
BJU International
|
September 27, 2020
Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma
David D'Andrea, Surena Matin, Peter C Black, et al.
BJU International
|
November 5, 2020
Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis
Francesco Soria, Peter C Black, Adrian S Fairey, et al.
The Journal of Urology
|
August 27, 2021
Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer
David D'Andrea, Peter C Black, Homayoun Zargar, et al.
The New England Journal of Medicine
|
May 27, 2011
Abiraterone and increased survival in metastatic prostate cancer
Johann S de Bono, Christopher J Logothetis, Arturo Molina, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
May 27, 2020
Continuing towards optimization of bladder cancer care in Canada: Summary of the third Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting
Wassim Kassouf, Armen Aprikian, Fred Saad, et al.
European Urology
|
March 21, 2014
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)
Dana E Rathkopf, Matthew R Smith, Johann S de Bono, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 98) with videos related to
Sort By:
Page
of 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 21, 2017
Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer
Emmanuel S Antonarakis, Scott T Tagawa, Giuseppe Galletti, et al.
Urologic Oncology
|
January 10, 2017
Quality indicators in the management of bladder cancer: A modified Delphi study
Satya R Khare, Armen Aprikian, Peter Black, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education
|
August 6, 2017
Development and Implementation of a Continuing Medical Education Program in Canada: Knowledge Translation for Renal Cell Carcinoma (KT4RCC)
Luke T Lavallée, Ryan Fitzpatrick, Lori A Wood, et al.
European Urology
|
May 20, 2015
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302
Fred Saad, Neal Shore, Hendrik Van Poppel, et al.
BJU International
|
September 27, 2020
Comparative effectiveness of neoadjuvant chemotherapy in bladder and upper urinary tract urothelial carcinoma
David D'Andrea, Surena Matin, Peter C Black, et al.
BJU International
|
November 5, 2020
Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer without hydronephrosis
Francesco Soria, Peter C Black, Adrian S Fairey, et al.
The Journal of Urology
|
August 27, 2021
Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer
David D'Andrea, Peter C Black, Homayoun Zargar, et al.
The New England Journal of Medicine
|
May 27, 2011
Abiraterone and increased survival in metastatic prostate cancer
Johann S de Bono, Christopher J Logothetis, Arturo Molina, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|
May 27, 2020
Continuing towards optimization of bladder cancer care in Canada: Summary of the third Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting
Wassim Kassouf, Armen Aprikian, Fred Saad, et al.
European Urology
|
March 21, 2014
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)
Dana E Rathkopf, Matthew R Smith, Johann S de Bono, et al.
Page
of 10